Check The following And Discover The Way To Excel Att DMXAA Simply

One study comparing entecavir (0.5mg/day) with adefovir (10?mg/day) in 132 patients with HBeAg-positive CHB found HBeAg seroconversion rates at 52 weeks of 15 and 22% respectively (48). Although entecavir resulted in a greater decrease from baseline HBV DNA levels than did adefovir through 2 years of treatment, the HBeAg seroconversion rates were 24 and 25% respectively (Fig. 1) (52). More recently, a long-term follow-up of continuous entecavir http://en.wikipedia.org/wiki/Resveratrol treatment has been reported (53, 54). In a cohort of 160 Chinese nucleoside-na?ve patients, undetectable serum HBV DNA levels and ALT normalization were achieved by 89 and 86% of the patients, respectively, after 3 years of entecavir treatment (53). An additional 12% of patients achieved HBeAg seroconversion during the third year http://www.selleckchem.com/products/Aloxistatin.html of treatment for an overall cumulative HBeAg seroconversion rate of 27% (53). An analysis of 98 treatment-na?ve HBeAg-positive patients who received 5 years of continuous entecavir with a treatment gap of ��35 days before recommencement of therapy showed that 94% of patients had HBV DNA of http://www.selleckchem.com/products/DMXAA(ASA404).html of Asian ethnicity, showed that HBeAg seroconversion occurred in 21 and 18% of patients respectively (Table 1) (7). In a follow-up analysis of the tenofovir-treated cohort, the HBeAg seroconversion rate increased to 26% at 2 years but remained unchanged during the third year of continuous tenofovir treatment (55, 56). In contrast to other oral NAs, higher HBeAg responses have been reported after 1 year of telbivudine treatment, particularly in Asian patients (6, 44). In the GLOBE trial, the rates of HBeAg seroconversion after 1 year of treatment were similar between patients receiving telbivudine 600?mg/day and patients receiving lamivudine 100mg/day (22.5 and 21.5% respectively) (6). The rate of HBeAg seroconversion increased with continuous treatment in both treatment groups. At 2 years of treatment, 30 and 25% of the patients in the telbivudine and lamivudine arms, respectively, achieved HBeAg seroconversion (P=0.095) (21). In a subanalysis of the GLOBE trial, patients with baseline HBV DNA levels